Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Stemetil 12.5 mg/ml Injection.
Pharmaceutical Form |
---|
Colourless sterile solution. |
Each 1 ml of Stemetil injection contains 12.5 mg prochlorperazine mesilate.
Excipients:
Each 1 ml of Stemetil injection contains 1 mg of sodium sulphite, 0.75 mg of sodium metabisulphite and 6 mg of sodium chloride.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Prochlorperazine |
Prochlorperazine belongs to the phenothiazine group. Prochlorperazine has a wide range of activity arising from its depressant actions on the CNS and its alpha-adrenergic blocking and weaker anti-muscarinic properties. It inhibits dopamine and prolactin-release-inhibitory factor, thus stimulating the release of prolactin. |
List of Excipients |
---|
Sodium sulphite anhydrous (E221) |
Stemetil injection is supplied in colourless glass ampoules in packs of 10 × 1 ml and 10 × 2 ml.
Not all pack sizes may be marketed.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as
Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0590
Date of first authorisation: 28 February 1973
Date of latest renewal: 16 September 2002
Drug | Countries | |
---|---|---|
STEMETIL | Australia, Cyprus, Estonia, Finland, Hong Kong, Ireland, Malta, New Zealand, Singapore, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.